The review, conducted in accordance with the PRISMA 2020 reporting guidelines, searched PubMed, Web of Science, Cochrane CENTRAL, and Google Scholar for peer-reviewed studies published between 2015 and 2025. The team led by Razan Suliman Alhumayed included randomized trials and observational studies reporting weight-related outcomes with either oral or subcutaneous semaglutide. Because the included studies differed substantially in population, formulation, dose, indication, comparator, design, and follow-up duration, the authors chose a narrative synthesis rather than quantitative pooling, a decision that shapes how their conclusions should be read.

The headline finding concerns the obesity-focused trials that excluded diabetes. In these studies, once-weekly subcutaneous semaglutide at the 2.4-milligram dose, the regimen approved specifically for chronic weight management, generally produced mean weight reductions of approximately 14 to 17 percent over 68 weeks. For a patient weighing 100 kilograms, that translates to a loss of roughly 14 to 17 kilograms, a magnitude that rivals some bariatric surgical outcomes and far exceeds what lifestyle intervention alone typically achieves. A trial testing a higher 7.2-milligram regimen produced even greater weight loss, hinting at a dose-response relationship that could define the next generation of obesity pharmacotherapy.

The biology behind these numbers is central to understanding why semaglutide behaves the way it does. As a long-acting glucagon-like peptide-1 receptor agonist, the drug reduces appetite and energy intake through both central and gastrointestinal mechanisms, mimicking a gut hormone that signals satiety to the brain and slows gastric emptying. Available in subcutaneous and oral formulations, semaglutide is used across two major indications, obesity and type 2 diabetes mellitus, with dosing that differs by formulation and indication. That dual identity is precisely why the review’s authors insist the evidence must be interpreted in a population-specific way.

In studies of people with type 2 diabetes, the weight-loss picture changes noticeably. Reductions in body weight were smaller in the diabetes trials than in the obesity-focused studies, but they were accompanied by clinically important improvements in HbA1c, the standard measure of long-term blood glucose control. This distinction matters enormously for clinical practice. A patient with diabetes starting semaglutide should expect meaningful metabolic benefits alongside more modest weight changes, while a patient without diabetes on the higher obesity dose can anticipate the larger reductions. The review also separated out the oral formulation studies, which primarily enrolled participants with type 2 diabetes, and interpreted them distinctly from the obesity-dose subcutaneous trials rather than blending the evidence together.

Safety findings form the other half of the story, and they are unlikely to surprise clinicians who have watched GLP-1 prescriptions soar. Gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were the most frequent tolerability issue across the included studies, and their frequency tended to increase during dose escalation and with higher cumulative exposure. This pattern reinforces the importance of gradual titration schedules, which are designed to let the body adapt before patients reach the maintenance dose. For most patients these effects are manageable, but they remain the leading reason people struggle with the treatment in its early months.

Beyond the digestive system, the review flagged several less common but clinically significant signals. Gallbladder events, treatment discontinuation, and a diabetic retinopathy signal observed in the SUSTAIN-6 cardiovascular outcomes trial all warrant careful, population-specific interpretation. The retinopathy finding, in particular, has implications for patients with diabetes and pre-existing eye disease, suggesting that clinicians should monitor vision in vulnerable groups when initiating therapy. None of these signals outweighs the drug’s demonstrated benefits, but they complicate the simple narrative of a miracle weight-loss injection that has dominated social media and popular coverage.

Perhaps the most sobering finding for the millions of people now taking or considering the drug concerns what happens when treatment stops. Weight regain after discontinuation was substantial in the withdrawal and extension studies included in the review. This observation underscores a biological reality that obesity specialists have long emphasized: obesity is a chronic disease, and pharmacotherapy that suppresses appetite works only while the drug is on board. Once treatment ends, the physiological drivers of weight regain reassert themselves, often erasing hard-won losses. The finding has significant implications for health systems and insurers weighing the cost of lifelong therapy against the consequences of relapse.

The review’s authors are careful about the limits of their own work. Because no quantitative pooling was performed, their conclusions are descriptive and should be interpreted cautiously. The strongest weight-loss evidence derives from obesity-focused subcutaneous trials, while findings from diabetes studies, cardiovascular outcome trials, oral formulation studies, and observational cohorts provide complementary but not directly interchangeable evidence. In an era when headlines often flatten these distinctions, the review serves as a reminder that the answer to how much weight a patient might lose depends heavily on who the patient is, which formulation they take, and at what dose.

What emerges from this comprehensive synthesis is a portrait of a genuinely transformative but imperfect therapy. Semaglutide is associated with clinically meaningful weight reduction, and for adults with obesity the 14 to 17 percent average losses achieved with the 2.4-milligram weekly injection represent a genuine turning point in obesity medicine. Yet the magnitude of benefit and the safety profile vary by population, formulation, dose, indication, and study design, and the substantial weight regain after discontinuation tempers any expectation of a permanent pharmacological fix. As prescriptions continue to climb worldwide, this review offers clinicians and patients alike a rigorously assembled evidence base for setting realistic expectations, managing side effects proactively, and planning for the long-term realities of chronic weight management.

Subject of Research: Efficacy and safety of semaglutide for weight loss in adults with overweight or obesity

Article Title: Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis

Article References: Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis. (n.d.). https://doi.org/10.1186/s12902-026-02641-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02641-z

Keywords: semaglutide, obesity, weight loss, GLP-1 receptor agonists, systematic review, type 2 diabetes, gastrointestinal side effects, weight regain, subcutaneous injection, oral semaglutide, HbA1c, drug safety

The study drew on administrative claims data from Optum’s deidentified Clinformatics Data Mart Database, which captures health records from large commercial and Medicare Advantage plans spanning all 50 US states. Researchers identified adults with confirmed diagnoses of both type 2 diabetes and established atherosclerotic cardiovascular disease who initiated oral semaglutide or another noninsulin glucose-lowering therapy between October 2019 and April 2024. After propensity score matching to balance baseline characteristics, the analysis compared 10,878 new users of oral semaglutide against 28,639 users of other noninsulin therapies, and conducted additional matched comparisons against specific drug classes, including dipeptidyl peptidase 4 inhibitors and sodium-glucose cotransporter 2 inhibitors. An as-treated approach was the primary analysis, with intention-to-treat sensitivity analyses confirming robustness.

The investigators assessed a battery of cardiovascular endpoints, ranging from the classic 3-point definition of major adverse cardiovascular events—ischemic stroke, myocardial infarction, and cardiovascular-related death—to broader composites that add hospitalization for unstable angina and heart failure, as well as modified versions that substitute all-cause death. Death was categorized as cardiovascular-related when claims showed a cardiovascular primary diagnosis within 30 days before death, while other events required an inpatient claim with a qualifying ICD-10-CM diagnosis code in the primary position. This multi-layered endpoint strategy matters because composite measures aggregate more events than their individual components, providing greater statistical power to detect treatment differences in a real-world population where follow-up periods are often short.

The headline finding was striking. Compared with users of other noninsulin glucose-lowering therapies, new users of oral semaglutide had a 17 percent lower risk of 3-point major adverse cardiovascular events and a 21 percent lower risk of the modified 3-point version. The benefits extended across the endpoint spectrum: oral semaglutide initiation was associated with a 26 percent lower risk of 5-point major adverse cardiovascular events, a 27 percent lower risk of the modified 5-point measure, and a 16 percent lower risk of 2-point events. Individually, oral semaglutide users experienced 23 percent lower risk of ischemic stroke and 29 percent lower risk of all-cause death, though the differences in myocardial infarction and cardiovascular-related death did not reach statistical significance in this dataset.

The class-specific comparisons sharpened the picture. Against matched users of dipeptidyl peptidase 4 inhibitors, each group comprising 7,218 patients, oral semaglutide users had a 22 percent lower risk of 3-point major adverse cardiovascular events, a 24 percent lower risk of the modified version, a 39 percent lower risk of ischemic stroke, and a 36 percent lower risk of all-cause death. Against sodium-glucose cotransporter 2 inhibitor users, the comparison was somewhat narrower, with 7,491 oral semaglutide users matched against 21,572 SGLT2 inhibitor users, yet oral semaglutide still delivered a 21 percent lower risk of 3-point events, a 22 percent lower risk of modified 3-point events, and significant reductions across the broader 5-point and 2-point composites. These are notable gains considering SGLT2 inhibitors themselves carry established cardiovascular benefits, meaning oral semaglutide outperformed an already cardioprotective comparator.

The economic implications were also meaningful. Oral semaglutide users accumulated fewer hospitalizations and lower overall medical costs than their counterparts on other therapies. Specifically, they had 19 percent fewer all-cause inpatient visits, 19 percent lower all-cause inpatient costs, and roughly $2,927 lower all-cause medical costs per patient per year compared with users of other noninsulin therapies. Against dipeptidyl peptidase 4 inhibitors, the savings were larger: 31 percent fewer all-cause inpatient visits and nearly $4,972 lower annual all-cause medical costs. Emergency room visits and costs were the notable exception, showing no significant differences in most comparisons, suggesting the cost advantages concentrate in inpatient and outpatient care rather than acute unscheduled visits.

The findings dovetail with the SOUL randomized clinical trial, which demonstrated that oral semaglutide was superior to placebo in reducing cardiovascular events among people with type 2 diabetes and established cardiovascular disease or chronic kidney disease, showing a 14 percent reduction in 3-point major adverse cardiovascular events. The real-world cohort had a slightly older average age than the trial population, a higher proportion of women, and broader representation of race, ethnicity, and geography, making it a useful complement to the trial’s controlled conditions. The US Food and Drug Administration has since approved oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes at high risk, including those without prior cardiovascular events, expanding its potential reach.

What makes oral semaglutide scientifically interesting is the chemistry behind the pill. Peptides like semaglutide are normally destroyed by digestive enzymes and cannot cross the intestinal wall, which is why GLP-1 receptor agonists have historically required injection. Oral semaglutide overcomes this by co-formulation with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, known as SNAC, an absorption enhancer that enables localized uptake of the peptide through the stomach lining without disrupting absorption of other molecules. This technological achievement matters clinically because injection aversion remains a real barrier for many patients, and an oral option with comparable cardiovascular protection could help combat therapeutic inertia in diabetes management.

The authors caution that the observational design cannot fully establish causation, and that claims data lack clinical granularity on kidney function, blood pressure, lipids, smoking, and lifestyle factors that may influence cardiovascular risk. Negative-control analyses examining outcomes theoretically unrelated to the drugs, such as breast or prostate cancer and arm or shoulder fractures, found no differences between groups, providing some reassurance against unmeasured confounding. Follow-up was relatively short, averaging roughly nine to ten months, and the study population was limited to the US health care setting. Still, the consistency of the results with the SOUL trial, combined with prior real-world evidence showing cardiovascular benefits of once-weekly injectable semaglutide, builds a coherent case that this class of drugs genuinely protects the heart in high-risk patients, whether delivered by needle or by pill.

Subject of Research: Real-world cardiovascular outcomes of oral semaglutide in adults with type 2 diabetes and atherosclerotic cardiovascular disease.

Article Title: Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Article References: Tan, X., Liang, Y., Zhong, C., Xie, L., Guevarra, M., Swift, C., & de Havenon, A. (2026). Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01919-8

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01919-8

Keywords: oral semaglutide, type 2 diabetes, cardiovascular outcomes, major adverse cardiovascular events, GLP-1 receptor agonist, DPP4 inhibitors, SGLT2 inhibitors, ischemic stroke, real-world evidence, SNAC absorption, Diabetes Therapy, comparative effectiveness

The motivation behind T-BEAT stems from a persistent treatment gap in Japan. According to the International Diabetes Federation, the age-standardized prevalence of diabetes among Japanese adults aged 20 to 79 years reached 8.1 percent in 2024, and the number of affected adults has been climbing steadily for a quarter of a century. Despite the availability of increasingly powerful medications, the Japan Diabetes Clinical Data Management Study Group reported in 2021 that more than half of individuals with type 2 diabetes failed to reach the glycated hemoglobin target of below 7 percent recommended to prevent complications, and only 5.5 percent achieved normoglycemia, defined as HbA1c below 6 percent. These figures underscore a sobering reality: even in a country with an advanced healthcare system, glycemic control remains stubbornly inadequate for a majority of patients, and the burden of diabetic complications continues to accumulate.

Tirzepatide, approved in Japan in 2022, combines the activity of both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in a single once-weekly injection. In the phase 3 SURPASS J-mono trial, tirzepatide monotherapy at doses of 5 to 15 mg weekly outperformed dulaglutide in reducing both HbA1c and body weight, while the SURPASS J-combo trial showed that tirzepatide added to a single oral antidiabetes drug produced remarkable glycemic control accompanied by dose-dependent weight loss. Oral semaglutide, approved in Japan in 2020, has similarly demonstrated significant reductions in HbA1c and body weight in Japanese clinical practice through the PIONEER REAL Japan study, and in phase 3 testing it beat dulaglutide on both glycemic and weight measures. Most recently, the SOUL cardiovascular outcomes trial reported that once-daily oral semaglutide significantly reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular or kidney disease, adding an important dimension to the comparison between these two incretin-based therapies.

What makes T-BEAT distinctive is its focus on the earliest phase of pharmacological treatment. The study enrolled adults with type 2 diabetes who were completely naive to oral antidiabetes drugs, managing their condition with diet and exercise alone, or who were receiving just one oral agent other than oral semaglutide. Participants had to have an HbA1c between 7 and 10 percent and a body mass index between 23 and 35 kg/m² at screening, and anyone with prior exposure to GLP-1 receptor agonists, insulin, tirzepatide, or oral semaglutide was excluded. This deliberately narrow population allows the investigators to isolate the effects of tirzepatide at a moment when timely intervention may have the greatest influence on long-term disease trajectory, a period that prior real-world research has largely overlooked.

The design of the study reflects the realities of observational research. Treatment decisions were made entirely by physicians according to routine clinical practice, with no interference from the study protocol. Participants were recruited between July 2024 and March 2025 at Japanese hospitals and clinics, mainly those staffed by endocrinologists and diabetes specialists. The primary endpoint is the mean change in HbA1c from baseline after up to 12 months of treatment with tirzepatide at 5 to 15 mg once weekly, with oral semaglutide at 7 to 14 mg once daily included as a reference treatment. Follow-up data will be collected at 3, 6, and 12 months after treatment initiation, and participants will be followed even if they discontinue the index medication and switch to another therapy, capturing the messy dynamics of real-world care that randomized trials typically exclude.

Beyond glycemic control, the study will track an unusually broad set of secondary outcomes. These include changes in body weight and percentage weight change, the proportion of participants achieving HbA1c targets of less than 5.7, 6.0, 6.5, and 7.0 percent and weight loss targets of at least 3, 5, 10, and 15 percent, changes in blood pressure, serum lipids, and liver function, treatment persistence over 12 months, and patient-reported treatment satisfaction measured with the validated Japanese versions of the Diabetes Treatment Satisfaction Questionnaire. The DTSQ status version was administered at baseline and the change version will be completed at the end of the observation period, each item rated on a seven-point scale, providing a standardized window into how patients actually experience these two very different delivery formats, one injectable and once weekly, the other oral and taken daily under strict fasting conditions.

The baseline data released with the design paper reveal meaningful patterns in how Japanese physicians are choosing between the two drugs. In the tirzepatide group of 290 participants, the mean age was 55.2 years, 45.2 percent were female, mean body weight was 79.6 kg, mean BMI was 29.3 kg/m², and mean baseline HbA1c was 8.0 percent. The oral semaglutide group of 279 participants was slightly older at 58.8 years on average, with 35.5 percent female, a mean weight of 77.2 kg, mean BMI of 28.2 kg/m², and mean HbA1c of 7.8 percent. Notably, the tirzepatide group contained proportionally more individuals with a BMI above 30 kg/m², 42.8 percent versus 26.5 percent, and more with HbA1c above 8.5 percent, 21.4 percent versus 14.3 percent, suggesting that physicians reserve the injectable dual agonist for patients with greater obesity and more pronounced hyperglycemia, consistent with Japan Diabetes Society guidance that favors tirzepatide for weight reduction in individuals with obesity.

Dyslipidemia was the most common comorbidity in both groups, affecting 62.1 percent of the tirzepatide cohort and 67.7 percent of the oral semaglutide cohort, followed by hypertension at roughly half of participants in each group. Metabolic dysfunction-associated fatty liver disease and diabetic nephropathy were also frequent, and about 40 percent of participants in both groups were already taking an oral antidiabetes drug, most commonly a sodium glucose co-transporter 2 inhibitor or a biguanide. Because treatment assignment in an observational study is driven by clinical judgment rather than randomization, the investigators applied inverse probability of treatment weighting across 13 prespecified baseline covariates, including HbA1c, BMI, lipid profile, kidney function, age, sex, diabetes duration, cardiovascular history, concomitant medication use, and physician specialty. Before weighting, nine covariates showed imbalances exceeding the accepted threshold; after weighting, all absolute standardized mean differences fell below 0.1 and all variance ratios stayed within the acceptable range, establishing a statistically sound foundation for the effectiveness comparisons to come.

The study was designed with 540 participants in mind, providing 90 percent power to detect a 0.5 percent difference in HbA1c change between the two treatments, and will employ two complementary analytical estimands: one assuming strict adherence to the index therapy and one reflecting effectiveness as observed regardless of discontinuation or treatment change. The study, funded by Eli Lilly Japan and Tanabe Pharma Corporation and approved by the Takahashi Clinic Ethics Committee, is expected to be completed in 2026. Although no longitudinal outcomes are available yet, the authors argue that publishing the design and baseline characteristics before results, a practice modeled by the DISCOVER program and PIONEER REAL Japan, strengthens transparency and allows the scientific community to judge the comparability of the cohorts in advance. If the 12-month findings confirm that tirzepatide delivers its trial-level potency in everyday practice, physicians in Japan and beyond may gain the confidence to deploy this dual incretin agonist earlier in the disease course, potentially reshaping the treatment algorithm for a condition in which more than half of patients still fall short of their glycemic goals.

The choice of comparators in T-BEAT reflects a broader shift in Japanese diabetes care toward incretin-based therapies. Under the Japan Diabetes Society treatment algorithm, physicians are encouraged to select agents through stepwise assessment of underlying pathophysiology inferred from body mass index, with GLP-1 receptor agonists and tirzepatide both listed as candidates for individuals with obesity, in whom insulin resistance is presumed. For patients without obesity, in whom insulin secretory deficiency is thought to dominate, careful attention to further weight loss is advised. This framework helps explain why tirzepatide and oral semaglutide are often weighed against each other for similar patient profiles, even though they differ in route of administration and mechanism of action.

Patient preference may also shape early treatment decisions. Japanese individuals with type 2 diabetes have been reported to favor oral therapy, giving oral semaglutide a practical advantage, while the once-weekly injectable format of tirzepatide may suit patients who prefer less frequent dosing. Because prior real-world studies of tirzepatide were conducted mainly outside Japan in heterogeneous populations at varied disease stages, T-BEAT’s focus on newly treated, early-stage patients in routine Japanese practice addresses a genuine evidence gap. Its findings on treatment satisfaction and persistence may prove as informative as the glycemic results themselves.

Subject of Research: Real-world effectiveness of tirzepatide for early glycemic and weight management in type 2 diabetes in Japan

Article Title: Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study

Article References: Waki, H., Kagitani, H., Osaga, S., Inoue, M., & Yabe, D. (2026). Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01916-x

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01916-x

Keywords: tirzepatide, oral semaglutide, type 2 diabetes, T-BEAT study, Japan, HbA1c, weight management, observational study, GIP/GLP-1 receptor agonist, real-world evidence, diabetes therapy, treatment satisfaction

The study, published in the American Journal of Psychiatry, examined whether an oral formulation could be more acceptable than earlier injectable approaches tested in AUD populations. That matters because adherence and patient preferences often determine whether a pharmacologic strategy has any chance of scaling beyond tightly controlled settings.

Semaglutide acts through the glucagon-like peptide-1 (GLP-1) pathway, which influences appetite, reward processing, and metabolic signaling. Researchers hypothesized that these same biological effects could translate into less alcohol-seeking behavior—particularly in people who want—or feel forced—to cut back without necessarily aiming for immediate abstinence.

To test this, investigators ran an eight-week randomized, double-blind, placebo-controlled trial involving 50 adults with moderate-to-severe AUD who were actively seeking treatment. Participants were assigned to receive oral semaglutide or a placebo while researchers tracked drinking patterns, cravings, and alcohol-related consequences.

Across the trial, those taking oral semaglutide showed fewer heavy drinking days and lower alcohol consumption per drinking occasion. The intervention also corresponded with reduced day-to-day alcohol cravings, alongside fewer alcohol-related problems and an improved overall drinking risk level.

Notably, the study also reported reduced cannabis use days, hinting at broader effects on substance-related behaviors rather than a narrow, alcohol-only change. While not every laboratory-based measure shifted in controlled tests, the real-world pattern of drinking outcomes was consistent.

Importantly, the medication was generally well tolerated, with most side effects described as mild. High adherence and strong completion rates supported the feasibility of administering oral semaglutide in an AUD-like context where drop-out can otherwise obscure signal.

Experts say these results could widen the toolbox for AUD, a condition that remains difficult to treat and has seen no new FDA-approved medications in nearly two decades. Even modest reductions in heavy drinking, researchers argue, can meaningfully improve health, family stability, and safety.

The authors emphasize that larger and longer-term trials are needed to confirm the effect size, determine optimal dosing strategies, and clarify who benefits most. Funding included support from the National Institute on Alcohol Abuse and Alcoholism, and larger studies are planned.

Subject of Research: Alcohol Use Disorder (AUD); oral semaglutide
Article Title: Not provided
News Publication Date: “published today” (exact date not provided)
Web References: https://doi.org/10.1176/appi.ajp.20260003
References: American Journal of Psychiatry (article via DOI above)
Image Credits: Not provided
Keywords: Alcohol Use Disorder, semaglutide, GLP-1, heavy drinking, randomized clinical trial, addiction medicine, cravings, oral medication